A year after the US Federal Trade Commission set its sights on pharmaceutical mergers, the agency has teamed up with the Department of Justice for a broad review of their merger guidelines. The new initiative once again shows that mergers in pharma and other industries may face additional hurdles.
On 18 January, the FTC and DOJ issued a request for information seeking public comment on how they can...







